Loading company…
PathoQuest provides biosafety testing and biopharmaceutical characterization using its iDTECT® platform.
Founded in 2010 in Paris, France, PathoQuest offers biosafety testing and biopharmaceutical characterization through its iDTECT® platform, which uses Next Generation Sequencing (NGS) to test for viral safety and genetic characterization at GMP standards. The company has raised EUR 10.67 mn, with its most recent deal on November 9, 2021, led by SHS Gesellschaft für Beteiligungsmanagement. In 2022 it reported revenue of EUR 4,131,441.80 and EBITDA of EUR -3,642,753.10.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in